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Monoclonal antibodies are standard therapeutics for
several cancers including the anti-CD20 antibody
rituximab for B cell non-Hodgkin lymphoma (NHL).
Rituximab and other antibodies are not curative
and must be combined with cytotoxic chemotherapy
for clinical benefit. Here we report the eradication
of human NHL solely with a monoclonal antibody
therapy combining rituximab with a blocking anti-
CD47 antibody. We identified increased expression
of CD47 on human NHL cells and determined that
higher CD47 expression independently predicted
adverse clinical outcomes in multiple NHL subtypes.
Blocking anti-CD47 antibodies preferentially enabled
phagocytosis of NHL cells and synergized with ritux-
imab. Treatment of human NHL-engrafted mice with
anti-CD47 antibody reduced lymphoma burden and
improved survival, while combination treatment
with rituximab led to elimination of lymphoma and
cure. These antibodies synergized through a mecha-
nism combining Fc receptor (FcR)-dependent and
FcR-independent stimulation of phagocytosis that
might be applicable to many other cancers.
INTRODUCTION
Emerging evidence has demonstrated that monoclonal anti-
bodies (mAbs) either alone or in combination are an effectivemodality for cancer treatment (Adams and Weiner, 2005).
Although therapies combining a mAb with chemotherapeutic
agents are effective in several human cancers, antibodies alone
are not curative. Antibodies effective against cancer are believed
to function by several mechanisms including antibody-depen-
dent cellular cytotoxicity (ADCC), stimulation of complement-
dependent cytotoxicity (CDC), inhibition of signal transduction,
or direct induction of apoptosis (Cheson and Leonard, 2008).
Non-Hodgkin lymphoma (NHL) is the fifth most common
cancer in the United States consisting of indolent and aggressive
subtypes with a 5 year overall survival ranging from 25%–75%
(The International Non-Hodgkin’s Lymphoma Prognostic
Factors Project, 1993). The anti-CD20 antibody, rituximab (Rit-
uxan), is a standard therapy for many CD20-positive B cell
lymphomas and significantly improves long-term survival in
combination with conventional chemotherapy (Cheson and Leo-
nard, 2008). As a single agent or in combination with chemo-
therapy, rituximab is not curative in the majority of B cell NHL
patients and rituximab resistance has been observed (reviewed
in Cheson and Leonard, 2008).Multiple lines of evidence indicate
that rituximab acts at least in part by engaging Fc receptors
(FcRs) on immune effector cells, such as NK cells and macro-
phages, and stimulating effector functions such as ADCC (Glen-
nie et al., 2007; Nimmerjahn and Ravetch, 2007). Although resis-
tance has been reported to occur through several mechanisms
(Cartron et al., 2004), there has been limited development of
agents that can overcome this resistance.
Immune effector cells, including NK cells and phagocytes, are
critical to the efficacy of many anticancer antibodies. Phagocytic
cells, including macrophages and dendritic cells, express signal
regulatory protein alpha (SIRPa), which binds CD47, a widelyCell 142, 699–713, September 3, 2010 ª2010 Elsevier Inc. 699
expressed transmembrane protein (Brown and Frazier, 2001).
CD47-mediated activation of SIRPa initiates a signal transduc-
tion cascade resulting in inhibition of phagocytosis (reviewed in
Jaiswal et al., 2010). In identifying a role for CD47 in cancer path-
ogenesis, we previously demonstrated that forced expression of
mouse CD47 on a human leukemia cell line facilitated tumor
engraftment in immunodeficient mice through the evasion of
phagocytosis (Jaiswal et al., 2009). We further demonstrated
that this mechanism could be targeted therapeutically in human
acute myeloid leukemia (AML) with a blocking anti-CD47 anti-
body that enabled phagocytosis and eliminated AML stem cells
(Majeti et al., 2009). Based on this antibody mechanism, we
hypothesized that the combination of a blocking anti-CD47
antibody with a second FcR-activating antibody would both
prevent an inhibitory signal and deliver a positive stimulus,
resulting in the synergistic phagocytosis and elimination of tar-
get cells. Here, we tested this antibody synergy hypothesis by
investigating the combination of a blocking anti-CD47 mAb
with rituximab against human NHL.
RESULTS
CD47 Expression Is Increased on NHL Cells Compared
to Normal B Cells
We examined CD47 protein expression on primary human NHL
samples and normal B cells by flow cytometry. Compared to
both normal peripheral blood and germinal center B cells,
CD47 was more highly expressed on a large subset of primary
patient samples from multiple B cell NHL subtypes (Figure 1A
and Figure S1A available online), including diffuse large B cell
lymphoma (DLBCL), B cell chronic lymphocytic leukemia
(B-CLL), mantle cell lymphoma (MCL), follicular lymphoma (FL),
marginal zone lymphoma (MZL), and pre-B acute lymphoblastic
leukemia (pre-B ALL). Across NHL subtypes, we found differing
levels of CD47 expression that also varied within each NHL
subtype (Figure 1B).
Increased CD47 Expression Correlates with a Worse
Clinical Prognosis and Adverse Molecular Features
in Multiple NHL Subtypes
Having previously shown a correlation between CD47 mRNA
and protein expression (Majeti et al., 2009), we assessed CD47
mRNA expression across NHL subtypes for associations with
morphologic and molecular subgroups using gene expression
data from previously described patient cohorts (Table S1) and
investigated the prognostic implications of increased CD47
expression in disease outcome. Higher CD47 expression was
associated with adverse prognosis in DLBCL, B-CLL, and MCL
(Figures 1C–1E). In patients with DLBCL, whether treated with
or without rituximab-based combination chemotherapy (Fig-
ure 1C and Figure S1B), higher CD47 expression was signifi-
cantly associated with risk of death. This increased risk was
largely due to disease progression (Figure S1C), a finding vali-
dated in an independent cohort of patients using quantitative
RT-PCR on fixed archival specimens (Figure S1D).
We next investigatedwhether increasedCD47 expression was
associated with known adverse molecular features in NHL.
In DLBCL, prior studies have identified two distinct subgroups700 Cell 142, 699–713, September 3, 2010 ª2010 Elsevier Inc.based on the presumed cell of origin of tumors: normal germinal
center B cells (GCB-like), which are associated with a favorable
clinical outcome, or activated blood memory B cells (ABC-like),
which are associated with a poor clinical outcome (Alizadeh
et al., 2000; Rosenwald et al., 2002). CD47 expression was sig-
nificantly higher in ABC-like DLBCL (Figure 1F and Figure S1E).
CD47 expression was not found to have independent prog-
nostic value within GCB and ABC subtypes, suggesting a strong
association with the cell-of-origin classification of DLBCL.
Higher CD47 expression was also associated with unmutated
immunoglobulin heavy chain variable regions (IgVH) in CLL
(Figure 1G and Figure S1E) and significantly correlated with
the proliferative index in MCL (Figure 1H), both known adverse
prognostic factors (Katzenberger et al., 2006; Oscier et al.,
2002; Rosenwald et al., 2003). In multivariate analyses, CD47
expression remained prognostic of disease progression inde-
pendent from the international prognostic index in DLBCL (The
International Non-Hodgkin’s Lymphoma Prognostic Factors
Project, 1993) and two major prognostic factors in CLL: IgVH
mutation status and ZAP-70 status (Figure S1G). Within the
small MCL cohort, a multivariate model did not find independent
prognostic value for CD47 when considering the proliferation
index (data not shown).
Blocking Anti-CD47 Antibodies Enable Phagocytosis
of NHL Cells by Macrophages and Synergize
with Rituximab In Vitro
We first tested the ability of anti-human CD47 antibodies to
enable phagocytosis of human NHL cell lines, primary NHL cells,
and normal peripheral blood (NPB) cells by humanmacrophages
in vitro. Incubation of NHL cells in the presence of IgG1 isotype
control or anti-CD45 IgG1 antibody did not result in significant
phagocytosis; however, two different blocking anti-CD47 anti-
bodies (B6H12.2 and BRIC126) enabled phagocytosis of NHL
cells but not NPB cells (Figures 2A and 2B).
Next, we repeated the in vitro phagocytosis assays with
mouse macrophages. Incubation of NHL cells in the presence
of IgG1 isotype control or anti-CD45 IgG1 antibody did not result
in significant phagocytosis; however, phagocytosis of NHL cells
was observed with blocking antibodies to CD47 (B6H12.2 and
BRIC126), whereas no phagocytosis was observed with a non-
blocking antibody (2D3) (Figure 2B). Disruption of the CD47-
SIRPa interaction with an anti-mouse SIRPa antibody also
resulted in significant phagocytosis (Figure 2B).
Given variable expression of CD47 on primary NHL, we inves-
tigated by two independent methods whether CD47 expression
levels correlated with the degree of anti-CD47 antibody-medi-
ated phagocytosis. First, lentiviral shRNA vectors were used to
knock down expression of CD47 in Raji cells. Several clones
were generated with a range of CD47 knockdown (Figures S2A
and S2B). Those clones with a greater than 50% reduction in
CD47 expression (shCD47-1 and shCD47-2) demonstrated
a significant reduction in anti-CD47 antibody-mediated phago-
cytosis (Figure S3C). In the second approach, a statistical anal-
ysis demonstrated a positive correlation between CD47 expres-
sion and degree of anti-CD47 antibody-mediated phagocytosis
with both mouse and human macrophage effector cells
(Figure S2D).
Figure 1. CD47 Expression Is Increased on NHL Cells Compared to Normal B Cells, Confers aWorse Clinical Prognosis, and Correlates with
Adverse Molecular Features in Multiple NHL Subtypes
(A) CD47 expression on normal peripheral blood (PB) B cells (CD19+), normal germinal center (GC) B cells (CD3CD5CD20+CD10+CD38+), and NHL B cells
(CD19+) was determined by flow cytometry, and mean fluorescence intensity was normalized for cell size. Each point represents a different patient sample:
DLBCL = 2, CLL = 15, MCL = 4, FL = 6, MZL = 2, and pre-B ALL = 1 (****p < 0.0001). Normalized mean expression (and range) for each population were: normal
PB B cells 420.9 (267.3–654.0), normal GC B cells 482.5 (441.1–519.9), and NHL 888.5 (270.1–1553).
(B) CD47 expression across NHL subtypes including DLBCL (DL, n = 15), MCL (n = 34), FL (n = 28), and B-CLL (n = 14) was determined as in (A). Normalizedmean
expression (and range) for each population were: DL 725.7 (261.2–1344), MCL 1055 (444.2–2196), FL 825.1 (283.6–1546), CLL 713.6 (432.8–1086) (*p < 0.05).
(C–E) Prognostic influence of CD47 mRNA expression is shown on overall (C and E) and event-free (D) survival of patients with DLBCL, B-CLL, and MCL.
For DLBCL and CLL, stratification into low and highCD47 expression groups was based on an optimal threshold determined bymicroarray analysis; this cutpoint
was internally validated for both DLBCL and CLL and also externally validated in an independent DLBCL cohort. For MCL, stratification relative to themedian was
employed as an optimal cutpoint could not be defined. Significance measures are based on log-likelihood estimates of the p value, when treating CD47 expres-
sion as a continuous variable, with corresponding dichotomous indices also provided in Table S1.
(F–H) CD47 mRNA expression is shown in relation to cell-of-origin classification for DLBCL (F), immunoglobulin heavy chain mutation status (IgVH) for CLL (G),
and proliferation index for MCL (H). Error bars represent upper and lower quartiles (F and G). Analyses for (C)–(H) employed publicly available datasets for NHL
patients (Table S1). NGC = normal germinal center, ABC = activated B cell-like, GCB = germinal center B cell-like.
See also Figure S1 and Table S1.
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Figure 2. Blocking Antibodies against CD47 Enable Phagocytosis of NHL Cells by Macrophages and Synergize with Rituximab In Vitro
(A) CFSE-labeled NHL cells were incubated with humanmacrophages and the indicated antibodies and examined by immunofluorescence microscopy to detect
phagocytosis (arrows). Photomicrographs from a representative NHL sample are shown.
(B) Phagocytic indices of primary human NHL cells (blue), normal peripheral blood (NPB) cells (red), and NHL cell lines (purple, orange, and green) were deter-
mined using human (left) andmouse (middle) macrophages. Antibody-induced apoptosis (right panel) was tested by incubating NHL cells with the indicated anti-
bodies or staurosporine without macrophages and assessing the percentage of apoptotic and dead cells (% annexin V and/or PI positive).
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It has been reported that immobilized or crosslinked anti-
bodies against CD47 induce apoptosis of primary human
B-CLL cells, as well as several malignant lymphoid cell lines
(Kikuchi et al., 2004, 2005; Mateo et al., 1999; Uno et al.,
2007). Therefore, anti-CD47 antibodies might be predicted to
directly induce apoptosis of NHL cells that are then recognized
by macrophages and phagocytosed. Contrary to this prediction,
when NHL cells were incubated with anti-CD47 antibody in
the absence of macrophages, no induction of apoptosis was
observed when cells were incubated in suspension for either
2 hr (Figure 2B, right) or 8 hr (Figures S2E and S2F). Incubation
of NHL cells with immobilized anti-CD47 antibody resulted in
increased apoptosis compared to controls (Figures S2G and
S2H), consistent with prior reports (Mateo et al., 1999). Given
that phagocytosis of NHL cells occurs in the presence of soluble
anti-CD47 mAbs, it is unlikely that these mAbs induce apoptosis
of NHL cells that are then secondarily phagocytosed.
Next, we tested the ability of a blocking anti-CD47mAb to syn-
ergize with rituximab in the phagocytosis of NHL cells. We exam-
ined CD20 expression on NHL cells and found no difference
between normal B cells and NHL cells (Figures S2I and S2J).
Incubation of NHL cells with rituximab in the presence of mouse
or human macrophages resulted in significant phagocytosis
(Figures 2D and S2E). We then tested the synergy hypothesis
by isobologram analysis (Chou, 2008; Tallarida, 2006). Using
Raji, SUDHL4, and NHL17 cells, which express varying levels
of both CD47 and CD20 (Figure S2K), anti-CD47 antibody
synergized with rituximab or anti-human CD20 (mouse IgG2a)
antibody, as indicated by combination indices less than 1 (Fig-
ure 2C). In a second approach, in vitro phagocytosis assays
were conducted with primary NHL cells incubated with either
anti-CD47 antibody or rituximab alone, or both in combination
at half of the single agent dose. NHL cells exhibited a significant
increase in phagocytosis when incubated with the combination
compared to either antibody alone when using mouse (Fig-
ure 2D) or human (Figure 2E) macrophage effectors. No phago-
cytosis of NPB cells was observed with either antibody alone or
in combination with human macrophages (Figure 2E).
Ex Vivo Coating of NHLCells with an Anti-CD47Antibody
Inhibits Tumor Engraftment
Next, the ability of blocking anti-CD47 antibody to eliminate NHL
in vivo either alone or in combinationwith rituximabwas explored
by two separate treatment strategies. First, the effect of ex vivo
anti-CD47 antibody coating on the engraftment of human NHL
cells was tested. Luciferase-expressing Raji and SUDHL4 cell
lines were precoated ex vivo with anti-CD47, IgG1 isotype
control, or anti-CD45 antibody and transplanted intravenously
into SCID mice. Coating with anti-CD47 antibody prevented
engraftment of both cell lines (Figures 3A–3F). Coating of Raji
cells with rituximab also inhibited engraftment when trans-(C) Synergistic phagocytosis by anti-CD47 antibody (B6H12.2) and anti-CD20 m
indices (CI). CIobs indicates observed results, and the dashed line indicates the e
(D and E) Synergy between anti-CD47 antibody and rituximab in the phagocytosis
incubated with a combination of both antibodies compared to either antibody alon
cell line derived from primary sample NHL17.
***p < 0.001, ****p < 0.0001, *****p < 0.00001. Figure 2B p values represent compplanted into SCIDmice (Figure S3). In addition to these cell lines,
we identified a primary NHL patient specimen that engrafted in
NSG mice in the bone marrow upon intravenous transplantation
(Figures S5A and S5B). As with the cell lines, ex vivo coating of
these primary cells with anti-CD47 antibody, but not controls
(Figure 3G), resulted in complete inhibition of bone marrow
engraftment (Figure 3H).
Combination Therapy with Anti-CD47 Antibody and
Rituximab Eliminates Lymphoma in Both Disseminated
and Localized Human NHL Xenotransplant Models
In the second treatment strategy, mice were first engrafted with
NHL and then administered single or combination antibody
therapy. To best model NHL, we established disseminated and
localized xenotransplantation models in NSG mice that are defi-
cient in T, B, and NK cells (Shultz et al., 2005) but retain phago-
cyte effector cells. In the disseminated model, luciferase-
expressing Raji cells were transplanted intravenously into adult
NSGmice. Two weeks later, these mice were administered daily
injections of either control mouse IgG, anti-CD47 antibody, ritux-
imab, or anti-CD47 antibody and rituximab. Anti-CD47 antibody
treatment decreased the lymphoma burden in these mice (Fig-
ures 4A and 4B) and significantly prolonged survival compared
to control IgG, although all mice eventually died (Figure 4C and
Table S2). Similar results were seen with rituximab and were
not statistically different compared to anti-CD47 antibody (Fig-
ures 4A–4C and Table S2). In contrast, combination therapy
with anti-CD47 antibody and rituximab eliminated lymphoma in
60% of mice as indicated by long-term survival (Figure 4C) and
the absence of luciferase-positive lymphoma (data not shown)
more than 4 months after the end of treatment. In humans, ritux-
imab efficacy is thought to be primarily mediated by bothmacro-
phages and NK cells (Nimmerjahn and Ravetch, 2007; Taylor
and Lindorfer, 2008). Given that NSGmice lack NK cells, we con-
ducted a similar experiment in NK cell-containing SCIDmice and
observed similar therapeutic responses as in NSG mice (Figures
S4A and S4B).
In the localized NHL model, luciferase-expressing Raji cells
were transplanted subcutaneously in the right flank of NSG
mice. Once tumors were palpable (approximately 2 weeks),
mice were treated with antibody therapy. Mice treated with
anti-CD47 antibody or rituximab demonstrated a decreased
rate of lymphoma growth compared to control IgG-treated
mice as measured by both luciferase signal and tumor volume
(Figures 4D–4F) but, like controls, eventually had to be sacrificed
due to enlarged tumor growth. In contrast, mice treated with the
combination of anti-CD47 antibody and rituximab demonstrated
complete elimination of lymphoma, with 86% of treated mice
having no measurable mass or luciferase-positive lymphoma
4 weeks after the end of therapy (Figures 4D–4F and Figures
S4C–S4E). Moreover, all showed no evidence of tumor growth,Abs was examined by isobologram analysis and determination of combination
xpected results if antibodies were additive.
of NHL and NPB cells was assessed by determining the phagocytic index when
e at twice the dose, with either mouse (D) or human (E) macrophages. NHL17*:
arison against IgG1 isotype control antibody. See also Figure S2.
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Figure 3. Ex Vivo Coating of NHL Cells with an Anti-CD47 Antibody Inhibits Tumor Engraftment
(A–F) Luciferase-expressing Raji (A) and SUDHL4 (C) cells were assessed for ex vivo antibody coating by flow cytometry. SCIDmice transplanted with Raji (B) and
SUDHL4 (D) were subject to bioluminescent imaging (1-IgG1 isotype control, 2-anti-CD45, 3 and 4-anti-CD47, 5-luciferase negative control). Bioluminescence
for Raji (E) and SUDHL4 (F) engrafted mice was quantified (n = 3 per antibody condition). No tumor engraftment was observed in mice transplanted with anti-
CD47-coated cells compared to IgG-coated cells (p < 0.05) for both Raji and SUDHL4, as assessed by bioluminescent imaging. Data are represented as
mean ± standard deviation (SD).
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remained relapse free, and were alive at over 197 days after
tumor engraftment. Out of six mice achieving a complete remis-
sion, five remained relapse free whereas onemouse died of non-
tumor-related causes (Figure 4E). For both disseminated and
localized xenograft models, expression of CD47 and CD20 in
transplanted Raji cells did not differ from Raji cells in culture
(Figure S4F).
Combination Therapy with Anti-CD47 Antibody
and Rituximab Eliminates Lymphoma in Primary Human
NHL Xenotransplant Mouse Models
NHL cell lines have been valuable for the evaluation of therapeu-
tics, but they may not accurately recapitulate the heterogeneity
of the primary disease. We report here two newmouse xenograft
models for NHL in which intravenous transplantation of cells
from a DLBCL patient (NHL7/SUNHL7) and a FL patient
(NHL31/SUNHL31) give rise to robust lymphoma engraftment
in the bone marrow and/or peripheral blood (Figure S1A and
Figure S5A). Primary DLBCL cells were transplanted into mice,
which 2 weeks later were treated with daily injections of anti-
bodies for 14 days. Treatment with anti-CD47 antibody either
alone or in combination with rituximab eliminated human
lymphoma in the bone marrow, whereas treatment with rituxi-
mab resulted in a reduction of disease in 60% of mice (Figures
5A and 5B). Mouse hematopoietic cells were unaffected by anti-
body therapy (Figure S5E). Treatment was then discontinued,
and all mice were monitored for survival. Mice treated with either
anti-CD47 antibody or rituximab alone had a significantly longer
survival compared to mice treated with control IgG, but all even-
tually died secondary to disease due to widespread organ
dissemination on autopsy (Figure 5C, data not shown). Most
significantly, 8 out of 9 mice (89%) administered combination
antibody treatment were cured of lymphoma, as indicated by
long-term disease-free survival more than 4 months after the
end of treatment (Figure 5C and Table S3) with no detectable
lymphoma in the bone marrow (data not shown). In a second
primary model, FL cells were transplanted intravenously in a
similar manner. CD20+CD10+ lymphoma engraftment in the
peripheral blood and bone marrow was detected after 8 weeks.
At this time, mice were treated with a single intraperitoneal injec-
tion of either control IgG, anti-CD47 antibody, rituximab, or the
combination and then followed for disease progression. A single
dose of anti-CD47 antibody alone or in combination with rituxi-
mab eliminated lymphoma both in the peripheral blood (Fig-
ure 5D) and in bone marrow (Figure 5E). In contrast, a single
dose of rituximab enabled a partial reduction in tumor burden
that rebounded back to baseline levels in the peripheral blood
with no tumor reduction observed in the bonemarrow. The differ-
ence in anti-CD47 antibody clearance of lymphoma as a single
dose in FL-engrafted mice (Figures 5D and 5E) compared to
multiple dose therapy in mice engrafted with DLBCL (Fig-
ure 5B) or Raji (Figure 4) may be due to cell-intrinsic differences
in antibody sensitivity between different NHL subtypes or due to(G) Bulk lymphoma cells from a human NHL patient were assessed for ex vivo a
(H) Compared to IgG1 isotype control, anti-CD47 antibody pretreatment inhib
engrafted similarly to controls (p = 0.54). All p values were determined using Fish
Error bars represent SD (E and F). See also Figure S3.different anti-CD47 antibody potencies in distinct tissue com-
partments (peripheral blood versus bone marrow (BM) versus
soft tissue compartments).
To assess the ability of these two primary NHL xenotransplant
models tomodel the disease, we compared histological sections
of the primary NHL specimen and the transplanted tumor. Similar
DLBCL and FL morphology was observed for NHL7 and NHL31,
respectively (Figure S5B). We next determined whether the per-
centages of macrophages infiltrating the tumor differed between
the primary patient and the xenografted tumor. For NHL31, the
percentage of infiltrating human macrophages (CD68+) in the
primary lymph node was similar to the percentage of infiltrating
mouse macrophages (F4/80+) in bone marrow of transplanted
mice (Figure S5C). Analyzing infiltrating macrophage frequency
by flow cytometry, no difference was observed between the
primary specimen and xenograft for either NHL7 or NHL31
(Figure S5D).
Synergy between Anti-CD47 Antibody and Rituximab
Does Not Occur through NK Cells or Complement
Rituximab can eliminate malignant cells via apoptosis, NK cell-
mediated ADCC, and CDC (reviewed in Smith, 2003). However,
it is not known whether anti-CD47 antibody also enables ADCC
or CDC in addition to phagocytosis. Therefore, we investigated
whether anti-CD47 antibody alone could induce antitumor
effects by macrophage-independent mechanisms, and whether
synergy with rituximab could occur through these modalities.
First, to investigate possible synergy in direct apoptosis, NHL
cells were incubated with either anti-CD47 antibody/rituximab
alone or in combination without macrophages, and cell death
was measured. No synergistic apoptosis was observed when
NHL cells were incubated with soluble (Figure 6A and Fig-
ure S6A) or immobilized (Figures S6B and S6C) antibodies.
Furthermore, crosslinking of soluble anti-CD47 antibody alone
or in combination with rituximab by macrophages did not induce
increased apoptosis of nonphagocytosed NHL cells compared
to IgG1 isotype control, whereas rituximab induced a slight
increase in apoptosis (Figure S6D). No synergistic apoptosis
was observed in this context (Figure S6D). The small increase
in apoptosis upon antibody treatment was not FcR dependent
given that results were similar with macrophages lacking the
Fcg subunit (Takai et al., 1994) (Figure S6D). Second, we inves-
tigated whether NK cells could mediate tumor elimination by
anti-CD47 antibody alone or in synergy with rituximab. A prior
report observed increased NK cell cytotoxicity of cancer cell
lines with an anti-CD47 antibody in vitro, though the mechanism
of targeting was not elucidated (Kim et al., 2008). We first deter-
mined whether human or mouse NK cells expressed SIRPa and
found that both human NK cells, CD3CD56+CD7+ (Milush et al.,
2009), as well asmouseNK cells, CD3DX5+, expressedminimal
to no SIRPa (Figure 6B). Next, the ability of anti-CD47 antibody
to induce NK cell-mediated ADCC through FcRs or by CD47-
SIRPa blockade was investigated. Utilizing human NK cells asntibody coating by flow cytometry.
ited engraftment of NHL cells (p < 0.0001) whereas anti-CD45-coated cells
er’s exact test.
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Figure 4. Combination Therapy with Anti-CD47 Antibody and Rituximab Eliminates Lymphoma in Both Disseminated and Localized Human
NHL Xenotransplant Mouse Models
(A) NSG mice transplanted intravenously with luciferase-expressing Raji cells were treated with the indicated antibodies (n = 8 per treatment group). Luciferase
imaging of representative mice from pre- and 10 days post-treatment are shown (A) and averaged for all mice in each treatment group (B).
(C) Kaplan-Meier survival analysis was performed (Table S2). p values compare IgG control to combination antibody treatment or anti-CD47 antibody/rituximab
single antibody to combination. Arrows indicate start (day 14) and stop (day 35) of treatment.
(D) Luciferase-expressing Raji cells were transplanted subcutaneously in the flank of NSG mice. When palpable tumors (0.1 cm3) formed, treatment
began with the indicated antibodies. Luciferase imaging of representative mice from each treatment group is shown before (day 0) and during (day 14)
treatment.
(E) Quantified bioluminescence was determined and averaged for all mice in each treatment group (n = 7).
(F) Tumor volume was measured with average volume shown. p values were derived from a two-way ANOVA and compared to IgG treatment.
*p < 0.05, ***p < 0.001, ****p < 0.0001. Complete remission was defined as the number of mice with no evidence of tumor at the indicated date. Relapse was
defined as the number of mice achieving a complete remission that later developed recurrence of tumor growth. For (E), one mouse that achieved a complete
remission died of non-tumor-related causes. Data presented in (B), (E), and (F) are mean values ± SD. See also Figure S4 and Table S2.
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Figure 5. Combination Therapy with Anti-CD47 Antibody and Rituximab Eliminates Lymphoma in Primary Human NHL Xenotransplant
Mouse Models
(A and B) Sublethally irradiated NSG mice were transplanted intravenously with cells from a primary DLBCL patient (NHL7) and treated with the indicated anti-
bodies. Flow cytometry of human lymphoma engraftment in the bone marrow of two representative mice is shown pre- and 14 days post-antibody treatment in
(A). Data from all mice are included in (B). **p < 0.01, comparing pre- and post-treatment values for each respective antibody treatment.
(C) Kaplan-Meier survival analysis (Table S3) of DLBCL-engrafted mice from each antibody treatment cohort is shown (nR 10 per antibody group), with p values
calculated comparing control IgG to combination antibody treatment or anti-CD47 antibody/rituximab single antibody to combination treatment. Arrows indicate
start (day14) and stop (day 28) of treatment.
(D and E) Mice engrafted intravenously with a primary FL patient sample (NHL31) were treated with a single dose of the indicated antibodies. Compared to IgG
control and rituximab, anti-CD47 antibody alone or in combination with rituximab eliminated tumor burden in the peripheral blood (p = 0.04, two-way ANOVA) and
bone marrow (p < 0.001, t test).
(E) Lyphoma engraftment in the bone marrow was determined 14 days post-treatment. Each antibody treatment group consisted of three mice.
For mice reported in (D) and (E), human lymphoma chimerism was between 5% and 25% in the peripheral blood and bone marrow. Error bars represent SD
(D and E). See also Figure S5 and Table S3.
Cell 142, 699–713, September 3, 2010 ª2010 Elsevier Inc. 707
Figure 6. Synergy between Anti-CD47 Antibody and Rituximab Does Not Occur through NK Cells or Complement
(A) NHL cells were incubated with the indicated soluble antibodies for 2 hr and the percentage of dead cells was calculated (% annexin V+ and/or 7-AAD+). No
statistically significant difference in%dead cells was observedwith the combination of anti-CD47 antibody and rituximab compared to either anti-CD47 antibody
alone (p = 0.24) or rituximab alone (p = 0.95).
(B) SIRPa expression is shown for both human and mouse NK cells as determined by flow cytometry.
(C and D) Chromium release assaysmeasuring ADCCwere performed in triplicate with human (C) andmouse (D) at an effector:target ratio of 17.5:1, and percent-
specific lysis is reported. Antibodies were incubated at 10 mg/ml except anti-CD47 full-length or F(ab0)2 antibody+rituximab (5 mg/ml).
(E) CDC assay with human complement was performed in duplicate. Compared to IgG1 isotype control, anti-CD47 antibody did not enable CDC (p > 0.2),
whereas rituximab did (p < 0.001) by two-way ANOVA for both SUDHL4 and NHL17*. Combination treatment with anti-CD47 antibody and rituximab did not
enable greater levels of CDC compared to rituximab (p = 0.78).
(F) CDC assay with mouse complement was performed in duplicate. Compared to IgG1 isotype control, anti-CD47 antibody did not enable CDC (p > 0.25)
whereas rituximab did (p = 0.03, p = 0.08, respectively) for both SUDHL4 and NHL17*. No difference in CDC between CD47 antibody+rituximab and rituximab
alone was observed (p > 0.13) for both SUDHL4 and NHL17*.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Error bars represent SD (C–F). NHL17* = primary NHL17 cells expanded in culture. See also Figure S6.
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effectors, anti-CD47 antibody did not induce increased ADCC of
Raji or SUDHL4 cells compared to IgG1 isotype control (Fig-
ure 6C). Although rituximab did enable ADCC of these two
NHL cell lines, no synergistic effect between anti-CD47 antibody
and rituximab was observed (p = 0.77, Figure 6C). As anti-CD47
antibody (B6H12.2) is a mouse IgG1 isotype, we repeated these
assays with mouse NK cells. Anti-CD47 antibody caused
increased ADCCof these twoNHL cell lines compared to isotype
control, whereas rituximab induced ADCC to a lesser degree
(Figure 6D). To test whether anti-CD47 antibody-mediated
ADCC was Fc dependent, we generated a F(ab0)2 fragment of
the anti-CD47 antibody (Figures S7B–S7I). The F(ab0)2 fragment
did not enable ADCC, indicating that the increased ADCC was
likely mediated through FcRs (Figure 6D). The combination of
anti-CD47 antibody or F(ab0)2 fragment with rituximab did not
induce a statistically significant increase in ADCC compared to
single agent therapy, indicating no synergistic effect. Third, we
investigated the role of complement in anti-CD47 antibody-
mediated cytotoxicity. Using either human (Figure 6E) or mouse
(Figure 6F) complement, anti-CD47 antibody did not induce CDC
of either an NHL cell line or a primary NHL sample, whereas
rituximab did induce significant CDC against both of these
samples. Moreover, the combination of anti-CD47 antibody
and rituximab did not induce increased CDC compared to ritux-
imab alone. Fourth, we investigated the relative contribution of
major components of macrophages, NK cells, and complement
in mediating the therapeutic effects of anti-CD47 antibody and
rituximab in vivo. Luciferase-labeled Raji cells were engrafted
intravenously into SCID mice, which have functional macro-
phages, NK cells, and complement. Mice were then separated
into cohorts receiving selective depletion of either macrophages
by clodronate, NK cells by anti-asialoGM1 antibody, comple-
ment by cobra venom factor, or a vehicle control. These cohorts
were then treated with combination anti-CD47 antibody and rit-
uximab therapy for 3 days, and tumor burden was measured
by bioluminescent imaging pre- and post-treatment. Compared
to vehicle control, NK cell and complement depletion had no
effect on tumor elimination by combination antibody therapy
(Figure S6E). In contrast, macrophage depletion significantly
abrogated the therapeutic effect, indicating that macrophages,
and not NK cells or complement, are required for combination
anti-CD47 antibody and rituximab-mediated elimination of NHL
in vivo.
Anti-CD47 Antibody Synergizes with Rituximab through
FcR-Independent and FcR-Dependent Mechanisms
We hypothesize that the observed synergy between an anti-
CD47 antibody and rituximab occurs through the combination
of two separate mechanisms for stimulating phagocytosis: (1)
FcR-independent through blockade of an inhibitory phagocytic
signal by anti-CD47 antibody, and (2) FcR-dependent through
delivery of a positive phagocytic signal by rituximab. We utilized
four independent methods to investigate this hypothesis. First,
synergistic phagocytosis was observed with the combination
of anti-SIRPa antibody and rituximab by isobologram analysis
(Figure 7A), and with a large panel of primary NHL samples (Fig-
ure 7B). Second, mouse macrophages lacking the Fcg receptor,
thereby incapable of enabling FcR-dependent phagocytosis(Takai et al., 1994), but still expressing SIRPa (Figure S7A),
were utilized as effector cells for phagocytosis of NHL cells incu-
batedwith either anti-CD47 antibody, anti-SIRPa antibody, ritux-
imab, or anti-CD47/anti-SIRPa antibody in combination with
rituximab. As predicted, anti-CD47 antibody and anti-SIRPa
antibody, but not rituximab, enabled phagocytosis of NHL cells,
without evidence of synergistic phagocytosis (Figure 7C).
Third, F(ab0)2 fragments of both anti-CD47 antibody and
rituximab were generated (Figures S7B–S7I) and utilized in
phagocytosis assays with NHL cells and wild-type macro-
phages. Anti-CD47 F(ab0)2 antibody synergized with rituximab
as demonstrated by isobologram analysis (Figure 7D). Addition-
ally, anti-CD47 F(ab0)2, but not rituximab F(ab0)2, enabled phago-
cytosis of NHL cells (Figure 7E). Consistent with the proposed
mechanism, synergistic phagocytosis was observed with the
combination of either full-length anti-CD47 or anti-CD47 F(ab0)2
with full-length rituximab, but not with any combination involving
rituximab F(ab0)2 (Figure 7E).
Fourth, synergistic phagocytosis was investigated in vivo
using GFP+ Raji cells engrafted in NSG mice. As single agents,
anti-CD47 antibody and rituximab enabled phagocytosis of
Raji cells engrafted in the liver as evidenced by an increased
percentage of mouse macrophages containing phagocytosed
GFP+ Raji cells (Figure 7F). Most significantly, combination
anti-CD47 antibody and rituximab treatment enabled signifi-
cantly increased phagocytosis compared to either single agent
demonstrating that synergistic phagocytosis occurred in vivo
(Figure 7F).
DISCUSSION
In this report, we identify a distinct mechanism of synergy
betweenmAbs in cancer therapy leading to cures in the absence
of chemotherapy. Specifically, we utilized a blocking anti-CD47
antibody in combination with the anti-CD20 antibody rituximab
to eradicate human NHL through a mechanism of synergy
involving FcR-independent enabling of phagocytosis by anti-
CD47 antibody and FcR-dependent stimulation of phagocytosis
by rituximab. In addition, the identification of CD47 expression
as a prognostic factor could be incorporated into standard clin-
ical prognostic considerations across multiple subtypes of NHL
and may be useful in risk-adapted therapy decision-making.
Although it is thought that many therapeutic mAbs for human
malignancies, including rituximab, function primarily through
NK cell-mediated ADCC, several lines of evidence indicate that
the therapeutic effect of anti-CD47 antibody alone or in combi-
nation with rituximab is mediated primarily through macrophage
phagocytosis. First, synergistic macrophage phagocytosis was
observed with combination anti-CD47 antibody and rituximab
in vitro, whereas no synergy was observed for direct apoptosis,
ADCC, or CDC (Figures 2C–2E, Figure S6, Figure 6A, and Figures
6C–6F). Second, phagocytosis of NHL cells in vivo was observed
with either anti-CD47 antibody or rituximab alone and, most
importantly, significantly increased with combination therapy
(Figure 7F). Third, the therapeutic effect of combination antibody
treatment was similar in an NHL xenotransplant model using
complement and NK cell-deficient NSG mice (Figure 4C) as in
complement and NK cell-competent SCID mice (Figures S4ACell 142, 699–713, September 3, 2010 ª2010 Elsevier Inc. 709
Figure 7. Anti-CD47 Antibody Synergizes with Rituximab through FcR-Independent and FcR-Dependent Mechanisms
(A) Isobologram analysis of phagocytosis induced by anti-SIRPa antibody and rituximab is shown for Raji cells and mouse macrophages.
(B and C) NHL cells were incubated in vitro with the indicated antibodies in the presence of wild-type (B) or Fcgr/ (C) mouse macrophages, and the phagocytic
index was determined.
(D) Isobologram analysis of phagocytosis induced by anti-CD47 F(ab0 )2 antibody and rituximab is shown for Raji cells and mouse macrophages.
(E) NHL cells were incubated with wild-type mouse macrophages in the presence of the indicated full-length or F(ab0)2 antibodies (single antibodies at 10 mg/ml,
combination antibodies at 5 mg/ml each) and the phagocytic index was determined.
(F) The level of in vivo phagocytosis measured as the percentage of mouse macrophages containing phagocytosed GFP+ Raji cells (hCD45GFP+F4/80+) was
determined by flow cytometry of livers from mice engrafted with GFP+ Raji cells and then treated with the indicated antibodies (see Experimental Procedures),
with each treatment group performed in duplicate. Compared to IgG control, anti-CD47 antibody and rituximab enabled increased levels of phagocytosis.
Compared to anti-CD47 antibody alone, combination anti-CD47 antibody and rituximab enabled higher levels of phagocytosis.
*p < 0.05, **p < 0.01, ****p < 0.0001. Error bars represent SD (E and F). See also Figure S7.
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and S4B), suggesting that macrophages alone are sufficient to
mediate the therapeutic effect. Fourth, depletion of macro-
phages, but not complement or NK cells, abrogated the syner-
gistic effect of anti-CD47 antibody in combination with rituximab
(Figure S6E). These studies highlight the importance of macro-
phages as effectors of anti-CD47 antibody therapy in human
NHL.
This study describes a mechanism of antibody synergy in the
elimination of NHL in the absence of chemotherapy. Combina-
tion antibody therapies for NHL have previously been investi-
gated, mostly in combination with rituximab, with some pro-
gressing to clinical trials. These include a humanized antibody
targeting the B cell antigen CD22 (epratuzumab) and galiximab,
a chimeric antibody targeting the costimulatory ligand CD80.
Phase I/II studies with either epratuzumab or galiximab in combi-
nation with rituximab demonstrate relative safety and clinical
responses equal to or greater than single agent therapy alone
(Leonard et al., 2005, 2007, 2008). Based on these results, phase
III trials are underway. Antibody combinations involving anti-
CD20 antibodies and antibodies to proapoptotic receptors are
also being explored preclinically (Daniel et al., 2007; Maddipatla
et al., 2007). These studies highlight the clinical potential of
combination antibody approaches in NHL patients.
Combination therapy with two or more mAbs possesses
several advantages compared to monotherapies in NHL or other
malignancies. First, therapy solely with monoclonal antibodies
targeting cancer-specific antigens could result in decreased
off-target toxicity compared to current therapeutic regimens
that utilize chemotherapy. Second, synergy between two distinct
antibody effector mechanisms, FcR-independent and FcR-
dependent as shown here, would result in increased therapeutic
efficacy. Third, antibody targeting of two distinct cell-surface
antigens would be more likely to eliminate cancer cells with
pre-existing epitope variants or epitope loss, such as those
reported in rituximab-refractory/resistant NHL patients (Foran
et al., 2001; Hiraga et al., 2009; Kennedy et al., 2004). Fourth,
a bispecific FcR-engaging antibody with one arm binding and
blocking CD47 and the other binding to a validated cancer anti-
body target (CD20) could reduce potential antibody toxicity,
while retaining the synergy effect, especially as CD47 is
expressed in multiple normal tissue types. Although we demon-
strated that an anti-mouse CD47 antibody is relatively nontoxic
to wild-type mice (Majeti et al., 2009), a clinical anti-human
CD47 antibody may have a different human toxicity profile that
could be overcome by a bispecific antibody.
In addition to its application in NHL, the reported mechanism
of antibody synergy provides proof-of-principle that a blocking
mAb directed against CD47 can synergize with an FcR-acti-
vating antibody to provide superior therapeutic efficacy. This
finding raises the possibility of potential synergy between an
anti-CD47 antibody and other clinically approved therapeutic
antibodies that may activate FcRs on immune effector cells for
the treatment of diverse human malignancies, including trastu-
zumab (Herceptin) for HER2-positive breast carcinomas, cetux-
imab (Erbitux) for colorectal carcinomas and head and neck
squamous cell carcinomas, alemtuzumab (Campath) for CLL
and T cell lymphoma, and others in development (Finn, 2008).
To date, we have demonstrated effective anti-CD47 antibodytargeting of several human cancers including AML (Majeti
et al., 2009), bladder cancer (Chan et al., 2009), and now NHL,
leading us to speculate that CD47 targeting will be effective
against a wide range of human cancers.
EXPERIMENTAL PROCEDURES
Cell Lines
A Burkitt’s lymphoma cell line (Raji) and a DLBCL cell line (SUDHL4) were
obtained from the American Type Culture Collection or generated in the lab.
The NHL17* cell line was generated from a patient with DLBCL by culturing
bulk cells in vitro with IMDM supplemented with 10% human AB serum for
1.5 months.
Human Samples
Normal human peripheral blood and human NHL samples were obtained from
the Stanford University Medical Center (Stanford, CA, USA) with informed
consent, according to an IRB-approved protocol (Stanford IRB# 13500) or
with informed consent from the Norwegian Radium Hospital (Oslo, Norway)
according to a Regional Ethic Committee (REK)-approved protocol (REK#
2.2007.2949). Normal tonsils for germinal center B cell analysis were obtained
from discarded tonsillectomy specimens from consented pediatric patients at
Stanford University Medical Center according to an IRB-approved protocol
(Stanford IRB# 13500).
Flow Cytometry Analysis
For analysis of normal peripheral blood cells, germinal center B cells, and
primary NHL cells, the following antibodies were used: CD19, CD20, CD3,
CD10, CD45, CD5, CD38 (Invitrogen, Carlsbad, CA, USA and BD Biosciences,
San Jose, CA, USA). Analysis of CD47 expression was performed with an anti-
human CD47 FITC antibody (clone B6H12.2, BD Biosciences). Cell staining
and flow cytometry analysis was performed as previously described (Majeti
et al., 2009).
Evaluation of Prognostic Value of CD47 in NHL
Gene expression and clinical data were analyzed for eight previously
described cohorts of adult NHL patients, including four studies of patients
with DLBCL, three with B-CLL, and one with MCL (detailed in Table S1). The
clinical end points analyzed included overall (OS), progression free (PFS),
and event-free survival (EFS), with events defined as the interval between
study enrollment and need for therapy or death from any cause, with data
censored for patients who did not have an event at the last follow-up visit.
See Extended Experimental Procedures for a detailed description of the
analyses.
Therapeutic Antibodies
Rituximab (anti-CD20, human IgG1) was obtained from the Stanford University
Medical Center, mouse anti-human CD20, IgG2a from Beckman Coulter
(Miami, FL, USA), and anti-CD47 antibody BRIC126, IgG2b from AbD Serotec
(Raleigh, NC, USA). Other anti-CD47 antibodies were used as in Majeti et al.
(2009). All in vivo antibody experiments were performed using the anti-CD47
B6H12.2 antibody.
In Vitro Isobologram Studies
In vitro phagocytosis assays were conducted with NHL cells incubated with
anti-CD47 antibody (B6H12.2), anti-CD20 IgG2a, or rituximab either alone or
in combination at concentrations from 1 mg/ml to 10 mg/ml. The concentration
of each antibody required to produce a defined single-agent effect (phagocytic
index) was determined for each cell type. Concentrations of the two antibodies
combined to achieve this same phagocytic index were then plotted on an
isobologram and the combination index (CI) determined. The CI was calcu-
lated from the formula CI = (d1/D1) + (d2/D2), whereby d1 = dose of drug
1 in combination to achieve the phagocytic index, d2 = dose of drug 2 in
combination to achieve the phagocytic index, D1 = dose of drug 1 alone to
achieve the phagocytic index, D2 = dose of drug 2 alone to achieve theCell 142, 699–713, September 3, 2010 ª2010 Elsevier Inc. 711
phagocytic index. A CI of less than, equal to, and greater than 1 indicates
synergy, additivity, and antagonism, respectively.
Annexin V Apoptosis Assays
Assays were performed as previously described (Majeti et al., 2009).
Preparation of Human and Mouse Immune Effector Cells, Immune
Effector Cytotoxicity Assays, and In Vivo Depletion of Immune
Effector Cells
See Extended Experimental Procedures.
Preparation of F(ab0)2 Fragments
See Extended Experimental Procedures.
Generation of Luciferase-Positive Cell Lines and Luciferase Imaging
Analysis
See Extended Experimental Procedures.
In Vivo Precoating Engraftment Assay
Assay were performed as previously described (Majeti et al., 2009). Precoated
cells were transplanted intravenously into SCID mice or sublethally irradiated
(200 rads) NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG). All experiments involving
mice were performed according to Stanford University institutional animal
guidelines.
In Vivo Antibody Treatment in a Disseminated Lymphoma
Xenograft Model
1.5 3 106 luciferase-labeled Raji cells were injected intravenously into the
retro-orbital sinus of 6- to 10-week-old SCID or NSG mice. Those mice with
luciferase-positive lymphoma were given daily intraperitoneal injections of
200 mg mouse IgG control, anti-CD47 antibody, rituximab, or 200 mg anti-
CD47 antibody + 200 mg rituximab for 3 weeks. Antibody treatment was
then stopped and mice were followed for survival analysis. A complete remis-
sion (CR) was defined as no evidence of lymphoma by bioluminescence at the
end of treatment. A relapse was defined as evidence of lymphoma by biolumi-
nescence after the end of treatment in a mouse with a prior CR.
In Vivo Antibody Treatment in a Localized Lymphoma
Xenograft Model
3 3 106 luciferase-labeled Raji cells were injected subcutaneously into the
right flank of 6- to 10-week-old NSGmice. Those mice with luciferase-positive
lymphoma were given daily intraperitoneal injections of 400 mg mouse IgG
control, 400 mg anti-CD47, 200 mg rituximab, or 400 mg anti-CD47 + 200 mg rit-
uximab for 4 weeks. Tumor volume was measured every 3–4 days using the
formula (length*width)/2. Antibody treatment was then stopped and mice
were followed for survival analysis.
In Vivo Antibody Treatment of Primary NHL-Engrafted Mice
23 106 NHL cells were transplanted intravenously via retro-orbital plexus into
sublethally irradiated NSG mice. Two to ten weeks later, bone marrow was
aspirated from these mice and those mice with evidence of human lymphoma
engraftment (hCD45+CD19/CD10+ bone marrow cells) were then treated with
the same antibody regimen as in the disseminated lymphoma model. After
14 days, bone marrow cells from these mice were aspirated and antibody
treatment was stopped and mice followed for survival analysis. A CR was
defined as no evidence of lymphoma in the BM at end of treatment. A relapse
was defined as evidence of lymphoma in the BM after end of treatment in
a mouse with a prior CR.
In Vivo Phagocytosis
In vivo phagocytosis was performed as previously described (Majeti et al.,
2009) analyzing mice transplanted with GFP+ Raji cells into adult NSG mice.
Mice were given a single dose of antibody and analyzed 4 hr later for in vivo
phagocytosis.712 Cell 142, 699–713, September 3, 2010 ª2010 Elsevier Inc.SUPPLEMENTAL INFORMATION
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